UK agency says Pfizer breast cancer drug too expensive

Pfizer’s breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain’s state-run health service, the country’s healthcare cost-effectiveness watchdog said on Friday. The logo of Dow Jones Industrial Average stock market index listed company Pfizer is pictured here in La Jolla, California April 21, 2016.

Latest Clinical Data from OncBioMune Supports Safety and Therapeutic…

In the ongoing Phase 1 clinical trial, ProscaVax is being evaluated for safety and efficacy in prostate specific antigen recurrent prostate cancer in hormone-naive and hormone-independent patients. Per protocol, 20 patients are expected to be enrolled in the 1a portion of the study, with therapy consisting of six ProscaVax induction vaccinations at a single dose.